Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2014 Jun 20;134(4):975–978.e5. doi: 10.1016/j.jaci.2014.05.019

Fig 2.

Fig 2

NLF were treated with TNFα and IL-17 for 72 hr, washed and then treated with IL-13 in increasing concentrations (0.1 to 2.5 ng/ml) for 24 hours. Increased IL13RA2 induction is associated with loss of IL-13 induced CCL26 production (A-B). Recovery of IL-13 induced CCL26 expression by blocking IL-13Rα2 with mAb (C). Pairwise analyses of transcriptome signature of NLF treated with IL-13 ± TNF/IL-17 pretreatment (PreTx), ± anti-IL-13Rα2 mAb (D). Also refer to E Fig 3.

HHS Vulnerability Disclosure